Skip to main content
Select Search Option
Menu
Weill Cornell Medicine
  • Weill Cornell Medicine
  • Care
  • Discover
  • Teach
Myeloma Center
Myeloma Center
Explore this Website
  • Home
  • About Us
    • Our Team
  • For Patients
    • About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
    • Multiple Myeloma
    • Amyloidosis
    • Other Plasma Cell Disorders
    • Myeloma Signs and Symptoms
    • Amyloidosis Signs and Symptoms
    • Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
    • Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
    • Multiple Myeloma and Plasma Cell Disorder Treatment
    • Understanding and Managing Side Effects
    • Your First Visit
      • Self-Referral
    • Support Groups and Helpful Links
    • Frequently Asked Questions
  • Referring Physicians
    • Refer a Patient
  • Research and Clinical Trials
    • Basic and Translational Research
    • Bibliography
  • Contact Us
  • Weill Cornell Medicine
  • Care
  • Discover
  • Teach
  • Home
  • About Us
  • For Patients
  • Referring Physicians
  • Research and Clinical Trials
  • Contact Us
  • Home
  • Bibliography
    • Basic and Translational Research
    • Bibliography

Bibliography

Found 3 results
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W-J, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S et al..  2018.  Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.. Leuk Lymphoma. 59(6):1364-1374.
Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.  2014.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
Our Location
Myeloma Center
Contact Us
  • Twitter
  • Facebook
  • YouTube
425 East 61st St
8th Floor
New York, NY 10065
Phone: (646) 962-6500
Fax: (212) 746-8961
  • About Us
    • Our Team
  • For Patients
    • About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
    • Multiple Myeloma
    • Amyloidosis
    • Other Plasma Cell Disorders
    • Myeloma Signs and Symptoms
    • Amyloidosis Signs and Symptoms
    • Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
    • Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
    • Multiple Myeloma and Plasma Cell Disorder Treatment
    • Understanding and Managing Side Effects
    • Your First Visit
    • Support Groups and Helpful Links
    • Frequently Asked Questions
  • Referring Physicians
    • Refer a Patient
  • Research and Clinical Trials
    • Basic and Translational Research
    • Bibliography
  • Contact Us
Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and individualized clinical care, making groundbreaking biomedical discoveries, and educating generations of exceptional doctors and scientists.
Weill Cornell Medicine NewYork - Presbyterian
© Weill Cornell Medicine.
  • Privacy & Legal
  • Careers
  • Giving
  • Directory
  • Web Accessibility Assistance